New drug trial aims to control aggressive sarcoma
NCT ID NCT06571734
Summary
This study is testing an oral drug called zanzalintinib (XL092) for people with advanced leiomyosarcoma, a type of cancer that has spread or cannot be removed by surgery. The main goal is to see if the drug can help control the cancer and keep it from getting worse for at least six months. Researchers will enroll about 29 patients who have had one prior treatment to take the daily pill and track their progress.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LEIOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.